L-正缬氨酸甲酯盐酸盐 | 56558-30-6

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 缬氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: L-正缬氨酸甲酯盐酸盐
• 中文别名: L-正缬氨酸甲脂盐酸盐；H-Nva-OMe• HCl
• 英文名称: methyl L-norvalinate hydrochloride
• 英文别名: L-norvaline methyl ester hydrochloride；norvaline methyl ester hydrochloride；methyl (S)-2-aminopentanoate hydrochloride；(S)-Methyl 2-aminopentanoate hydrochloride；methyl (2S)-2-aminopentanoate;hydrochloride
• CAS: 56558-30-6
• 化学式: C₆H₁₃NO₂*ClH
• 分子量: 167.636
• InChiKey: IODNYRVZHKRFIW-JEDNCBNOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.71
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  52.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2922499990
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: H-Nva-OMe HCl
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: H-Nva-OMe HCl
CAS number: 56558-30-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H13NO2.ClH
Molecular weight: 167.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  L-正缬氨酸甲酯盐酸盐 在 3 A molecular sieve 、 三乙酰氧基硼氢化钠 、 三乙胺 作用下， 以 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 methyl (2S)-2-[methyl-[(2S,3S)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentyl]amino]pentanoate
  参考文献：
  名称：

  N-Arylalkyl Pseudopeptide Inhibitors of Farnesyltransferase

  摘要：

  Inhibitors of Ras protein farnesyltransferase are described which are reduced pseudopeptides related to the C-terminal tetrapeptide of the Ras protein that signals farnesylation. Reduction of the carbonyl groups linking the first three residues of the tetrapeptide leads to active inhibitors which are chemically unstable. Stability can he restored by alkylating the central amine of the tetrapeptide. Studies of the SAR of these alkylated pseudopeptides with concomitant modification of the side chain of the third residue led to 2(S)-(2(S)-{[2(S)-(2(R)-amino-3-mercaptopropylamino)-3-(S)-methylpentyl]naphthalen-1-ylmethylamino}acetylamino)-4-methylsulfanylbutyric acid (11), a subnanomolar inhibitor. The methyl ester (10) of this compound exhibited submicromolar activity in the processing assay and selectively inhibited anchorage-independent growth of Rat1 cells transformed by v-ras at 2.5-5 mu M.

  DOI：

  10.1021/jm9800907
• 作为产物：
  描述：

  L-正缬氨酸 以 甲醇 为溶剂， 生成 L-正缬氨酸甲酯盐酸盐
  参考文献：
  名称：

  Nor-statine and nor-cyclostatine polypeptides

  摘要：

  多肽及其衍生物中含有诺斯他汀和诺环斯他汀，对抑制酶肾素的血管紧张素原裂解作用是有用的。

  公开号：

  US04814342A1

文献信息

• 特胺酸衍生物及其制备方法与应用
  申请人：安徽农业大学

  公开号：CN113402436A

  公开（公告）日：2021-09-17

  本发明提供一种特胺酸衍生物及其制备方法与应用。所述特胺酸衍生物的结构如下：其中，R选自甲基、甲氧基等；R1选自C1‑C4脂肪烃基、苯甲基等；R2选自氢、含有苯环的羰基、含有脂肪烃的羰基或C1‑C4脂肪烃基等。本发明提供的特胺酸衍生物与已报道的化合物相比，通过用天然氨基酸甲酯对先导化合物进行修饰和结构优化，筛选出的化合物对农作物的生长基本没有影响，能有效杀死多种害虫，而且残留的量很少且容易去除残留的化合物，对环境污染小，结构新颖，原料廉价易得，合成方法简单高效，社会效益和经济效益显著，适合工业化生产。
• MMP-13-SELECTIVE INHIBITOR
  申请人：SHIONOGI & CO., LTD.

  公开号：EP1997804A1

  公开（公告）日：2008-12-03

  Since it is thought that if the activity of MMP-13 can be inhibited, this will largely contribute to improvement or prevention of progession of pathological states, particularly, osteoarthritis (OA), resulting from or associated with the MMP-13 activity, the development of MMP-13 inhibitors is anticipated. There are provided a compound represented by the general formula (I): wherein R1 is optionally substituted aryl etc. Z is C1-C5 alkylene which may be substituted and may be interrupted with a substituent selected from Substituent group a etc.; A is the formula: (R6 and R7 are each independently halogen, lower alkyl etc.; m and n are each independently 0, 1, or 2); R2 is a hydrogen atom, optionally substituted lower alkyl etc.; R3 is a hydrogen atom, optionally substituted lower alkyl etc.; R4 is a hydrogen atom; or R3 and R4 may be taken together with an adjacent carbon atom to from a ring; R5 is hydroxy, lower alkyloxy etc.), or an optically active isomer, a pharmaceutically acceptable salt or a solvate thereof, and a pharmaceutical composition containing it as an active ingredient, which has the MMP-13 inhibiting activity.

  由于人们认为如果MMP-13的活性可以被抑制，这将在改善或预防病理状态的进展方面起到很大作用，特别是由于或与MMP-13活性相关的骨关节炎（OA），因此预期会开发MMP-13抑制剂。 提供了一个由通式（I）表示的化合物： 其中R1是可选择取代的芳基等。Z是可取代的C1-C5烷基，可以被取代并且可以被来自取代基团a等的取代基中断；A是式： （R6和R7各自独立地是卤素，较低烷基等；m和n各自独立地是0、1或2）；R2是氢原子，可选择取代的较低烷基等；R3是氢原子，可选择取代的较低烷基等；R4是氢原子；或R3和R4可以与相邻的碳原子一起形成环；R5是羟基，较低烷氧基等），或其光学活性异构体、药学上可接受的盐或其溶剂化合物，以及含有其作为活性成分的具有MMP-13抑制活性的药物组合物。
• Whole cell assay for inhibitors of cathepsin k
  申请人：Desmarais Sylvie

  公开号：US20070015234A1

  公开（公告）日：2007-01-18

  The present invention relates to a method of identifying and evaluating chemical inhibitors of cathepsin K activity in whole cells. The present invention also relates to probes that are capable of forming irreversible adducts with cathepsin K at the active site. The probes used in the instant invention comprise a radioactive functional group to allow the detection of the irreversible cathepsin K-probe adducts.

  本发明涉及一种在整体细胞中识别和评估组织蛋白酶K活性的化学抑制剂的方法。本发明还涉及能够与组织蛋白酶K在活性部位形成不可逆加合物的探针。本发明中使用的探针包含放射性功能团，以允许检测不可逆的组织蛋白酶K-探针加合物。
• PYRROLIDINONE GLUCOKINASE ACTIVATORS
  申请人：Berthel Steven Joseph

  公开号：US20090264445A1

  公开（公告）日：2009-10-22

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.

  提供的化合物为公式（I）： 以及药学上可接受的盐，其中取代基如说明书中所披露。这些化合物以及包含它们的药物组合物，可用于治疗代谢性疾病和障碍，例如，2型糖尿病。
• [EN] WHOLE CELL ASSAY INVOLVING CATHEPSIN S<br/>[FR] DOSAGE DE CELLULE ENTIERE ASSOCIE A LA CATHEPSINE S
  申请人：MERCK FROSST CANADA INC

  公开号：WO2005028424A1

  公开（公告）日：2005-03-31

  The present invention relates to a method of identifying and evaluating chemical inhibitors of cathepsin S activity in whole cells. The present invention also relates to probes that are capable of forming irreversible adducts with cathepsin S at the active site. The probes used in the instant invention comprise radioactive functional groups to allow the detection of the irreversible cathepsin S-probe adducts.

  本发明涉及一种在整个细胞中识别和评估蛋白酶S活性的化学抑制剂的方法。本发明还涉及能够与蛋白酶S在活性位点形成不可逆加合物的探针。本发明中使用的探针包括放射性功能基团，以便检测不可逆蛋白酶S-探针加合物。